National Center for Tumor Diseases (DE)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
180
Publications
2376
Citations
219654
i10-index
967
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Improved Survival with Ipilimumab in Patients with... | 2010 | 14949 |
Combined Nivolumab and Ipilimumab or Monotherapy i... | 2015 | 8008 |
Improved Survival with Vemurafenib in Melanoma wit... | 2011 | 7632 |
Overall Survival with Combined Nivolumab and Ipili... | 2017 | 5309 |
Nivolumab in Previously Untreated Melanoma without... | 2014 | 5280 |
Five-Year Survival with Combined Nivolumab and Ipi... | 2019 | 3570 |
Clonal neoantigens elicit T cell immunoreactivity ... | 2016 | 3036 |
Genomic correlates of response to CTLA-4 blockade ... | 2015 | 2918 |
Vaccination of melanoma patients with peptide- or ... | 1998 | 2862 |
Improved Overall Survival in Melanoma with Combine... | 2014 | 2607 |
Dirk Schadendorf is a researcher with 2376 publications and 219654 citations. They are affiliated with National Center for Tumor Diseases. Their research focuses on . With an h-index of 180, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Dirk Schadendorf and 250M+ other papers.
Citations per publication by year